

Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/R70DE60BE9B1EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: R70DE60BE9B1EN

Abstracts

The 7 major rheumatoid arthritis markets reached a value of US\$ 27.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 33.8 Billion by 2034, exhibiting a growth rate (CAGR) of 1.88% during 2024-2034.

The rheumatoid arthritis market has been comprehensively analyzed in IMARC's new report titled "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rheumatoid arthritis refers to a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and stiffness. In this condition, the body's immune system mistakenly attacks the synovial membrane, which lines the joints, resulting in inflammation, thickening of the synovium, and damage to the surrounding cartilage and bone. The most common symptoms are joint pain, stiffness, and swelling, which can be present in multiple joints and may worsen in the morning or after periods of inactivity. As the disease progresses, joints may become deformed, limiting mobility. The ailment can also affect other body parts, such as the lungs, eyes, heart, etc. The diagnosis of rheumatoid arthritis typically involves a combination of physical examination, medical history, blood tests, and imaging procedures. The physical exam includes assessing joint mobility, checking for swelling or tenderness, and looking for other signs of inflammation. Several blood tests are performed to look for specific antibodies and inflammatory markers. Numerous imaging studies, such as X-rays and ultrasounds, are also used to assess joint damage and monitor disease progression.

The rising cases of immune system dysfunction, which leads to inflammation, pain, and damage to the joints, are primarily driving the rheumatoid arthritis market. In addition to this, the increasing prevalence of associated risk factors, such as genetic

predisposition, excessive smoking, exposure to certain pollutants, infections, etc., is further bolstering the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and naproxen, for reducing inflammation and swelling in the joints is also creating a positive outlook for the market. Additionally, the ongoing advancements in the field of biomarker research are leading to the development of more accurate and sensitive tests for the ailment, such as anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) tests. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the inflating demand for disease-modifying antirheumatic drugs (DMARDs), including methotrexate, sulfasalazine, leflunomide, etc., which aid in slowing down the progression of the ailment by suppressing the immune system's attack on the joints, is expected to drive the rheumatoid arthritis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the rheumatoid arthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for rheumatoid arthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rheumatoid arthritis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the rheumatoid arthritis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the rheumatoid arthritis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current rheumatoid arthritis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the rheumatoid arthritis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the rheumatoid arthritis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the rheumatoid arthritis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of rheumatoid arthritis across the seven major markets?

What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by type across the seven major markets?

How many patients are diagnosed (2018-2034) with rheumatoid arthritis across the seven major markets?

What is the size of the rheumatoid arthritis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of rheumatoid arthritis?

What will be the growth rate of patients across the seven major markets?

Rheumatoid Arthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for rheumatoid arthritis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rheumatoid arthritis market?

What are the key regulatory events related to the rheumatoid arthritis market?

What is the structure of clinical trial landscape by status related to the rheumatoid arthritis market?

What is the structure of clinical trial landscape by phase related to the rheumatoid arthritis market?

What is the structure of clinical trial landscape by route of administration related to the rheumatoid arthritis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 RHEUMATOID ARTHRITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 RHEUMATOID ARTHRITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 RHEUMATOID ARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)
 - 7.7.4 Epidemiology by Gender (?2018-2034?)
 - 7.7.5 Epidemiology by Type (?2018-2034?)
 - 7.7.6 Diagnosed Cases (?2018-2034?)
 - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Epidemiology by Type (?2018-2034?)
 - 7.8.6 Diagnosed Cases (?2018-2034?)
 - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Epidemiology by Type (?2018-2034?)
 - 7.9.6 Diagnosed Cases (?2018-2034?)
 - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 RHEUMATOID ARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 RHEUMATOID ARTHRITIS - UNMET NEEDS

10 RHEUMATOID ARTHRITIS - KEY ENDPOINTS OF TREATMENT

11 RHEUMATOID ARTHRITIS - MARKETED PRODUCTS

- 11.1 List of Rheumatoid Arthritis Marketed Drugs Across the Top 7 Markets

- 11.1.1 Olumiant (Baricitinib) - Eli Lilly and Company/Incyte Corporation
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Rinvoq (Upadacitinib) - AbbVie
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Enbrel (Etanercept) - Pfizer
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Orencia (Abatacept) - Bristol-Myers Squibb
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Kevzara (Sarilumab) - Regeneron/Sanofi
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 RHEUMATOID ARTHRITIS - PIPELINE DRUGS

- 12.1 List of Rheumatoid Arthritis Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 ATI-450 - Aclaris Therapeutics
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 MabionCD20 - Mabion SA
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 Olokizumab - R-Pharm International, LLC
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 F8IL10 - Philogen
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 HB-adMSCs - Hope Biosciences
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. RHEUMATOID ARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. RHEUMATOID ARTHRITIS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 RHEUMATOID ARTHRITIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Rheumatoid Arthritis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Rheumatoid Arthritis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Rheumatoid Arthritis - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Rheumatoid Arthritis - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Rheumatoid Arthritis - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Rheumatoid Arthritis - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Rheumatoid Arthritis - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Rheumatoid Arthritis - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Rheumatoid Arthritis - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Rheumatoid Arthritis - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Rheumatoid Arthritis - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Rheumatoid Arthritis - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Rheumatoid Arthritis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Rheumatoid Arthritis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Rheumatoid Arthritis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Rheumatoid Arthritis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Rheumatoid Arthritis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Rheumatoid Arthritis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Rheumatoid Arthritis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Rheumatoid Arthritis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Rheumatoid Arthritis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Rheumatoid Arthritis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Rheumatoid Arthritis - Access and Reimbursement Overview

16 RHEUMATOID ARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 RHEUMATOID ARTHRITIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 RHEUMATOID ARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/R70DE60BE9B1EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R70DE60BE9B1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

